Anbio Biotechnology (NNNN)

Anbio Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	10.31	9.69	7.1
Short-Term Investments	-	-	1.57
Cash & Cash Equivalents	10.31	9.69	8.67
Cash Growth	-	11.75%	-
Receivables	4.62	1.88	-
Inventory	-	-	0.35
Other Current Assets	3.84	4.18	4.92
Total Current Assets	18.77	15.75	13.94
Goodwill and Intangibles	-	-	0.01
Other Long-Term Assets	-	0.06	0
Total Long-Term Assets	-	0.06	0.02
Total Assets	-	15.81	13.96
Accounts Payable	-	0.83	1.41
Other Current Liabilities	0.53	0.17	0
Total Current Liabilities	0.53	0.99	1.41
Total Liabilities	-	0.99	1.41
Retained Earnings	-	14.8	12.55
Shareholders' Equity	18.42	14.82	12.55
Net Cash / Debt	10.31	9.69	8.67
Net Cash / Debt Growth	-	11.75%	-
Working Capital	18.24	14.76	12.53

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).